Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAVEN 6: Emicizumab in Mild or Moderate Hemophilia A Without FVIII Inhibitors
NCT04158648Phase 3Completed
- Sponsor
- Roche
- Start
- Feb 2020
- Primary completion
- Oct 2021
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 3 trial of emicizumab in hemophilia A, sponsored by Roche. Started Feb 2020; status: completed.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT04158648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04158648.